Allerton Bishop is proud to be a market leader in Site Leadership talent. Having completed nine searches across the global market in 2026, we are in a strong position to share observations from our recent assignments.
Over the past six months alone, we have mapped the European market several times for senior pharmaceutical and CPG manufacturing leadership appointments.
The recurring theme? The ‘Site Head’ market is becoming increasingly difficult to define by job title, headcount or salary alone.
The strongest leaders are moving globally, taking responsibility for significant investment programmes and, in some of the most challenging cases, turning underperforming sites around.
It is increasingly rare that we receive a brief that is open to candidates from outside the client's immediate sector. Particularly in the current market, I am often asked to find a 'square peg for a square hole'.
Unlike almost any market we have experienced over the past 20 years, clients can afford to be demanding—and, in most cases, they can find exactly what they are looking for.
Across our recent searches, three themes stand out.
1. What does a European Site Head cost?
There is significant variation in Site Head compensation across Europe, but geography is only part of the equation.
The complexity of the manufacturing process, regulatory environment, site maturity, number of employees and strategic importance of the facility can all have a significant impact on compensation.
As a broad indication of what we are seeing in the market:
|
Manufacturing environment
|
Typical European base salary*
|
|
Consumer / Consumer Health / Packaged Goods
|
€140k–€220k
|
|
Oral Solid Dose / Small Molecule Pharma
|
€150k–€200k
|
|
API / Complex Small Molecule
|
€130k–€180k
|
|
Sterile / Aseptic Manufacturing
|
€170k–€250k
|
|
Biologics
|
€190k–€300k
|
|
ATMP / Cell & Gene Therapy
|
€200k–€325k+
|
|
Major Campus / Cluster / Multi-Site Leadership
|
€240k–€350k+
|
*Indicative market ranges. Compensation can vary materially depending on country, site FTE, CDMO versus manufacturer, strategic importance and overall package structure.
The interesting point is that salary doesn't necessarily move in a straight line with headcount.
The value of a Site Head—and therefore the package required—is often determined by the strategic importance of the facility within a company's manufacturing network.
A highly automated 350-person sterile or advanced therapies facility can carry enormous technical, regulatory and commercial complexity. The person leading it may therefore command a package comparable with a major Campus or even Cluster Head in another organisation.
2. Mobility remains a differentiator
One of the most consistent challenges in European pharmaceutical executive search is location.
Much of our search work in 2026 has been in locations that are less densely populated or relatively remote—often areas historically well suited to manufacturing because of available land, infrastructure and lower real-estate costs.
The result is that some of the industry's most important manufacturing operations are based in locations with relatively shallow local executive talent pools.
This becomes particularly challenging at Site Head and senior leadership level.
Senior manufacturing executives are typically at a stage of life where relocation affects far more than their own commute. Partner careers, children's education, housing, international schools, tax and connectivity can all become part of the recruitment process.
Employers willing to understand and support these factors are, in many cases, gaining access to the best talent available.
This means mobility has become a genuine component of executive talent.
For employers in challenging locations, the lesson is equally important: defining the relocation proposition should be part of the search strategy from day one—not something discussed only once the preferred candidate has been identified.
3. The best shortlist
One of the most interesting features of senior manufacturing searches is the variety of leaders who can legitimately make the same shortlist.
For a single Site Head appointment, we can find ourselves comparing someone currently leading an Operations function or Business Unit of 250–600 FTE, an established Site Director with responsibility for 1,000+ employees, and a Cluster or Regional Manufacturing Head overseeing several sites.
At first glance, that can look like an inconsistent shortlist.
It isn't.
It is rare for Allerton Bishop to agree a search brief based on one specific type of candidate. Instead, recent experience, technical relevance, leadership capability and key competencies form the must-have requirements.
We typically look to create a shortlist containing a balance of high-potential, proven and stepping-back-down talent.
The high-potential candidate may be leading a smaller operation and be ready for greater scale.
The proven candidate may already be running a directly comparable facility and offer immediate credibility.
The stepping-back-down candidate may have progressed into Cluster, Regional or Global leadership but be attracted back to direct Site Leadership by the scale of the challenge, investment programme or strategic importance of the facility.
Our objective is to provide genuine choice, market-wide analysis and a rigorous process that reaches the final stage with more than one credible option.
Headcount responsibility tells us something about leadership scale, but it doesn't tell us everything about leadership or technical complexity.
A 400-person advanced therapies or sterile manufacturing facility can present a very different leadership challenge from a mature 1,000-person conventional manufacturing site. Equally, a leader who has managed 1,000+ employees brings experience of organisational layers, communication and leadership at a scale that should not be underestimated.
The strongest shortlist requires hard-earned market knowledge, referencing, meticulous assessment and, ultimately, a degree of informed 'gut instinct'.
With CPHI approaching, we are keen to speak with pharmaceutical, biotech, CDMO and consumer health leaders about their manufacturing leadership priorities for 2027.
Will you be attending CPHI?
If you or a colleague will be in Milan, we would be interested to meet.
#meetatcphimilan2026